{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:38:34Z","timestamp":1788359914951,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11427-024-2790-7","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T04:49:50Z","timestamp":1736830190000},"page":"593-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK\/STAT signaling"],"prefix":"10.1007","volume":"68","author":[{"given":"Shan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingge","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2790_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri, A., Mahmood, F., Wittmann, M., and Helliwell, P. (2018). Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 14, 719\u2013730.","journal-title":"Expert Rev Clin Immunol"},{"key":"2790_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1365-2559.2005.01959.x","volume":"46","author":"I Berger","year":"2005","unstructured":"Berger, I., Weckauf, H., Helmchen, B., Ehemann, V., Penzel, R., Fink, B., Bernd, L., and Autschbach, F. (2005). Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathol-ogy 46, 490\u2013497.","journal-title":"Histopathol-ogy"},{"key":"2790_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11912-020-00926-7","volume":"22","author":"NM Bernthal","year":"2020","unstructured":"Bernthal, N.M., Ishmael, C.R., and Burke, Z.D.C. (2020). Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon\u2019s perspective. Curr Oncol Rep 22, 63.","journal-title":"Curr Oncol Rep"},{"key":"2790_CR4","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1089\/ten.tea.2008.0273","volume":"15","author":"B Bilgen","year":"2009","unstructured":"Bilgen, B., Ren, Y., Pei, M., Aaron, R.K., and Ciombor, D.M.K. (2009). CD14-negative isolation enhances chondrogenesis in synovial fibroblasts. Tissue Eng Part A 15, 3261\u20133270.","journal-title":"Tissue Eng Part A"},{"key":"2790_CR5","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1186\/ar2099","volume":"8","author":"J Bondeson","year":"2006","unstructured":"Bondeson, J., Wainwright, S.D., Lauder, S., Amos, N., and Hughes, C.E. (2006). The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 8, R187.","journal-title":"Arthritis Res Ther"},{"key":"2790_CR6","doi-asserted-by":"publisher","first-page":"791907","DOI":"10.3389\/fimmu.2021.791907","volume":"12","author":"R Caire","year":"2021","unstructured":"Caire, R., Audoux, E., Courbon, G., Michaud, E., Petit, C., Dalix, E., Chafchafi, M., Thomas, M., Vanden-Bossche, A., Navarro, L., et al. (2021). YAP\/TAZ: key players for rheumatoid arthritis severity by driving fibroblast like synoviocytes phenotype and fibro-inflammatory response. Front Immunol 12, 791907.","journal-title":"Front Immunol"},{"key":"2790_CR7","doi-asserted-by":"publisher","first-page":"10573","DOI":"10.7150\/thno.48666","volume":"10","author":"C Cao","year":"2020","unstructured":"Cao, C., Wu, F., Niu, X., Hu, X., Cheng, J., Zhang, Y., Li, C., Duan, X., Fu, X., Zhang, J., et al. (2020). Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis. Theranostics 10, 10573\u201310588.","journal-title":"Theranostics"},{"key":"2790_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21873\/cgp.20272","volume":"18","author":"C Cao","year":"2021","unstructured":"Cao, C., Zhang, Y., Cheng, J., Wu, F., Niu, X., Hu, X., Duan, X., Fu, X., Zhang, J., Zhang, X., et al. (2021). \u03b2-arrestin2 inhibits the apoptosis and facilitates the proliferation of fibroblast-like synoviocytes in diffuse-type tenosynovial giant cell tumor. Cancer Genomics Proteomics 18, 461\u2013470.","journal-title":"Cancer Genomics Proteomics"},{"key":"2790_CR9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/jor.25216","volume":"40","author":"AC Chandler","year":"2022","unstructured":"Chandler, A.C., Yakoub, M., Fujiwara, T., Donlin, L.T., Purdue, P.E., and Healey, J.H. (2022). Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor. J Orthopaedic Res 40, 1918\u20131925.","journal-title":"J Orthopaedic Res"},{"key":"2790_CR10","doi-asserted-by":"publisher","first-page":"970976","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp, J.S., Miller, M.A., Montgomery, K.D., Nielsen, T.O., O\u2019Connell, J.X., Huntsman, D., Rijn, M., Gilks, C.B., and West, R.B. (2007). Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 31, 970976.","journal-title":"Am J Surg Pathol"},{"key":"2790_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","volume":"10","author":"M Diller","year":"2019","unstructured":"Diller, M., Hasseli, R., H\u00fclser, M.L., Aykara, I., Frommer, K., Rehart, S., M\u00fcller-Ladner, U., and Neumann, E. (2019). Targeting activated synovial fibroblasts in rheumatoid arthritis by peficitinib. Front Immunol 10, 541.","journal-title":"Front Immunol"},{"key":"2790_CR12","first-page":"93","volume":"58","author":"A Fa\u0142ek","year":"2018","unstructured":"Fa\u0142ek, A., Niemunis-Sawicka, J., Wrona, K., Szczypi\u00f3r, G., Rzepecka-Wejs, L., Ci\u00e7szczyk, K., Burdan, M., Puderecki, M., Burzec, P., Marzec-Kotarska, B., Szumi\u0142o, J., and Burdan, F. (2018). Pigmented villonodular synovitis. Folia Med Cracov 58, 93\u2013104.","journal-title":"Folia Med Cracov"},{"key":"2790_CR13","first-page":"1329","volume":"5","author":"I Firmbach-Kraft","year":"1990","unstructured":"Firmbach-Kraft, I., Byers, M., Shows, T., Dalla-Favera, R., and Krolewski, J.J. (1990). tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5, 1329\u20131336.","journal-title":"Oncogene"},{"key":"2790_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2147\/DDDT.S359501","volume":"16","author":"X Gao","year":"2022","unstructured":"Gao, X., He, X., Oshima, H., Miyatake, D., Otsuka, Y., Kato, K., Cai, C., Wojtkowski, T., Song, N., Kaneko, Y., et al. (2022). Pharmacokinetics and safety of single and multiple doses of peficitinib (ASP015K) in healthy chinese subjects. Drug Des Devel Ther Volume 16, 1365\u20131381.","journal-title":"Drug Des Devel Ther Volume"},{"key":"2790_CR15","doi-asserted-by":"publisher","first-page":"884893","DOI":"10.1002\/cncr.33312","volume":"127","author":"H Gelderblom","year":"2021","unstructured":"Gelderblom, H., Wagner, A.J., Tap, W.D., Palmerini, E., Wainberg, Z.A., Desai, J., Healey, J.H., van de Sande, M.A.J., Bernthal, N.M., Staals, E.L., et al. (2021). Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer 127, 884893.","journal-title":"Cancer"},{"key":"2790_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn, H.L., Tong, S., McQuarrie, K., Vernon, C., Hanlon, J., Maclaine, G., Lenderking, W., Ye, X., Speck, R.M., Lackman, R.D., et al. (2016). Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther 38, 778\u2013793.","journal-title":"Clin Ther"},{"key":"2790_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese, M.C., Greenwald, M., Codding, C., Zubrzycka-Sienkiewicz, A., Kivitz, A.J., Wang, A., Shay, K., Wang, X., Garg, J.P., and Cardiel, M.H. (2017). Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatology 69, 932\u2013942.","journal-title":"Arthritis Rheumatology"},{"key":"2790_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40744-019-00167-6","volume":"6","author":"MC Genovese","year":"2019","unstructured":"Genovese, M.C., Greenwald, M.W., Gutierrez-Ure\u00f1a, S.R., Cardiel, M.H., Poiley, J.E., Zubrzycka-Sienkiewicz, A., Codding, C.E., Wang, A., He, W., Amos, R., et al. (2019). Two-year safety and effectiveness of peficitinib in moderate-to-severe rheumatoid arthritis: a phase IIb, open-label extension study. Rheumatol Ther 6, 503\u2013520.","journal-title":"Rheumatol Ther"},{"key":"2790_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","volume":"34","author":"SC Gupta","year":"2013","unstructured":"Gupta, S.C., Sung, B., Prasad, S., Webb, L.J., and Aggarwal, B.B. (2013). Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34, 508\u2013517.","journal-title":"Trends Pharmacol Sci"},{"key":"2790_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","volume":"18","author":"C Haan","year":"2011","unstructured":"Haan, C., Rolvering, C., Raulf, F., Kapp, M., Dr\u00fcckes, P., Thoma, G., Behrmann, I., and Zerwes, H.G. (2011). Jak1 has a dominant role over Jak3 in signal transduction through \u03b3c-containing cytokine receptors. Chem Biol 18, 314\u2013323.","journal-title":"Chem Biol"},{"key":"2790_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","volume":"118","author":"HM Hammar\u00e9n","year":"2019","unstructured":"Hammar\u00e9n, H.M., Virtanen, A.T., Raivola, J., and Silvennoinen, O. (2019). The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 118, 48\u201363.","journal-title":"Cytokine"},{"key":"2790_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4103\/0019-5154.193662","volume":"61","author":"A Hazra","year":"2016","unstructured":"Hazra, A., and Gogtay, N. (2016). Biostatistics series module 6: correlation and linear regression. Ind J Dermatol 61, 593\u2013601.","journal-title":"Ind J Dermatol"},{"key":"2790_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy, S.M. (2022). Deucravacitinib: first approval. Drugs 82, 1671\u20131679.","journal-title":"Drugs"},{"key":"2790_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X., and Wang, W. (2021). The JAK\/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther 6, 402.","journal-title":"Sig Transduct Target Ther"},{"key":"2790_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"Hume, D.A., and MacDonald, K.P.A. (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810\u20131820.","journal-title":"Blood"},{"key":"2790_CR26","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., and S\u00e8ve, P. (2019). JAK inhibitors for the treatment of autoimmune and inflammatory diseases. AutoImmun Rev 18, 102390.","journal-title":"AutoImmun Rev"},{"key":"2790_CR27","first-page":"93","volume":"62","author":"M Kager","year":"2022","unstructured":"Kager, M., Kager, R., Fa\u0142ek, P., Fa\u0142ek, A., Szczypi\u00f3r, G., Niemunis-Sawicka, J., Rzepecka-Wejs, L., Staros\u0142awska, E., and Burdan, F. (2022). Tenosynovial giant cell tumor. Folia Med Cracov 62, 93\u2013107.","journal-title":"Folia Med Cracov"},{"key":"2790_CR28","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2353\/ajpath.2006.050999","volume":"168","author":"HP Kiener","year":"2006","unstructured":"Kiener, H.P., Lee, D.M., Agarwal, S.K., and Brenner, M.B. (2006). Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol 168, 1486\u20131499.","journal-title":"Am J Pathol"},{"key":"2790_CR29","doi-asserted-by":"publisher","first-page":"e2000608","DOI":"10.1002\/adhm.202000608","volume":"9","author":"S Kim","year":"2020","unstructured":"Kim, S., Kim, E.M., Yamamoto, M., Park, H., and Shin, H. (2020). Engineering multi-cellular spheroids for tissue engineering and regenerative medicine. Adv Healthcare Mater 9, e2000608.","journal-title":"Adv Healthcare Mater"},{"key":"2790_CR30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N.A., Hordinsky, M., Dutronc, Y., Wu, W.S., McCollam, J., et al. (2022). Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 386, 1687\u20131699.","journal-title":"N Engl J Med"},{"key":"2790_CR31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/rheumatology\/kez526","volume":"59","author":"Y Kitanaga","year":"2020","unstructured":"Kitanaga, Y., Imamura, E., Nakahara, Y., Fukahori, H., Fujii, Y., Kubo, S., Nakayamada, S., and Tanaka, Y. (2020). In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology 59, 1957\u20131968.","journal-title":"Rheumatology"},{"key":"2790_CR32","doi-asserted-by":"publisher","first-page":"709719","DOI":"10.1002\/art.39955","volume":"69","author":"AJ Kivitz","year":"2017","unstructured":"Kivitz, A.J., Gutierrez-\u00fcre\u00f1a, S.R., Poiley, J., Genovese, M.C., Kristy, R., Shay, K., Wang, X., Garg, J.P., and Zubrzycka-Sienkiewicz, A. (2017). Peficitinib, a JAK Inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatology 69, 709719.","journal-title":"Arthritis Rheumatology"},{"key":"2790_CR33","first-page":"277","volume":"5","author":"JJ Krolewski","year":"1990","unstructured":"Krolewski, J.J., Lee, R., Eddy, R., Shows, T.B., and Dalla-Favera, R. (1990). Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 5, 277\u2013282.","journal-title":"Oncogene"},{"key":"2790_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo, S., Nakayamada, S., and Tanaka, Y. (2023). JAK inhibitors for rheumatoid arthritis. Expert Opin Investal Drugs 32, 333\u2013344.","journal-title":"Expert Opin Investal Drugs"},{"key":"2790_CR35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1161\/CIRCRESAHA.110.225730","volume":"108","author":"G Kung","year":"2011","unstructured":"Kung, G., Konstantinidis, K., and Kitsis, R.N. (2011). Programmed necrosis, not apoptosis, in the heart. Circ Res 108, 1017\u20131036.","journal-title":"Circ Res"},{"key":"2790_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/ard.2003.013029","volume":"63","author":"E Kunisch","year":"2004","unstructured":"Kunisch, E. (2004). Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheumatic Dis 63, 774\u2013784.","journal-title":"Ann Rheumatic Dis"},{"key":"2790_CR37","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb, Y.N. (2019). Pexidartinib: first approval. Drugs 79, 1805\u20131812.","journal-title":"Drugs"},{"key":"2790_CR38","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/biot.200700228","volume":"3","author":"R Lin","year":"2008","unstructured":"Lin, R., and Chang, H. (2008). Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 3, 1172\u20131184.","journal-title":"Biotechnol J"},{"key":"2790_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.5858\/arpa.2012-0165-CR","volume":"136","author":"DR Lucas","year":"2012","unstructured":"Lucas, D.R. (2012). Tenosynovial giant cell tumor: case report and review. Arch Pathol Lab Med 136, 901\u2013906.","journal-title":"Arch Pathol Lab Med"},{"key":"2790_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud, C.J. (2018). The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskeletal 10, 117\u2013127.","journal-title":"Ther Adv Musculoskeletal"},{"key":"2790_CR41","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2196\/ijmr.9325","volume":"7","author":"MJ Mastboom","year":"2018","unstructured":"Mastboom, M.J., Planje, R., and van de Sande, M.A. (2018). The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. Interact J Med Res 7, e4.","journal-title":"Interact J Med Res"},{"key":"2790_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4155\/fmc.14.149","volume":"7","author":"CJ Menet","year":"2015","unstructured":"Menet, C.J., Mammoliti, O., and L\u00f3pez-Ramos, M. (2015). Progress toward JAK1-selective inhibitors. Future Med Chem 7, 203\u2013235.","journal-title":"Future Med Chem"},{"key":"2790_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/7973568","volume":"2020","author":"L Meng","year":"2020","unstructured":"Meng, L., Ding, L., Yu, Y., Li, W., and Huang, T. (2020). JAK3 and TYK2 serve as prognostic biomarkers and are associated with immune infiltration in stomach adenocarcinoma. Biomed Res Int 2020, 1\u201315.","journal-title":"Biomed Res Int"},{"key":"2790_CR44","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand, E.F., Vital, E.M., Petri, M., van Vollenhoven, R., Wallace, D.J., Mosca, M., Furie, R.A., Silk, M.E., Dickson, C.L., Meszaros, G., et al. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001\u20131010.","journal-title":"Lancet"},{"key":"2790_CR45","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/art.41441","volume":"72","author":"A Najm","year":"2020","unstructured":"Najm, A., Masson, F.-., Preuss, P., Georges, S., Ory, B., Quillard, T., Sood, S., Goodyear, C.S., Veale, D.J., Fearon, U., et al. (2020). MicroRNA-17-5p reduces inflammation and bone erosions in mice with collagen-induced arthritis and directly targets the JAK\/STAT pathway in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatology 72, 2030\u20132039.","journal-title":"Arthritis Rheumatology"},{"key":"2790_CR46","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/rheumatology\/keab265","volume":"60","author":"P Nash","year":"2021","unstructured":"Nash, P. (2021). Clinical use of Jak 1 inhibitors for rheumatoid arthritis. Rheumatology 60, ii31\u2013ii38.","journal-title":"Rheumatology"},{"key":"2790_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo, N. (2016). Can you teach old drugs new tricks? Nature 534, 314\u2013316.","journal-title":"Nature"},{"key":"2790_CR48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/0046-8177(95)90226-0","volume":"26","author":"JX O\u2019connell","year":"1995","unstructured":"O\u2019connell, J.X., Fanburg, J.C., and Rosenberg, A.E. (1995). Giant cell tumor of tendon sheath and pigmented villonodular synovitis: immunophenotype suggests a synovial cell origin. Hum Pathol 26, 771\u2013775.","journal-title":"Hum Pathol"},{"key":"2790_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","volume":"40","author":"S Ottaviani","year":"2011","unstructured":"Ottaviani, S., Ayral, X., Dougados, M., and Gossec, L. (2011). Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheumatism 40, 539\u2013546.","journal-title":"Semin Arthritis Rheumatism"},{"key":"2790_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CCO.0000000000000853","volume":"34","author":"E Palmerini","year":"2022","unstructured":"Palmerini, E., and Staals, E.L. (2022). Treatment updates on tenosynovial giant cell tumor. Curr Opin Oncol 34, 322\u2013327.","journal-title":"Curr Opin Oncol"},{"key":"2790_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","volume":"51","author":"E Palmerini","year":"2015","unstructured":"Palmerini, E., Staals, E.L., Maki, R.G., Pengo, S., Cioffi, A., Gambarotti, M., Picci, P., Daolio, P.A., Parafioriti, A., Morris, C., et al. (2015). Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer 51, 210\u2013217.","journal-title":"Eur J Cancer"},{"key":"2790_CR52","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni, F., Reynaud, E.G., and Stelzer, E.H.K. (2007). The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8, 839\u2013845.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2790_CR53","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/17453674.2012.678803","volume":"83","author":"G Park","year":"2012","unstructured":"Park, G., Kim, Y.S., Kim, J.H., Lee, S., Song, S.Y., Choi, E.K., Yi, S.Y., and Ahn, S.D. (2012). Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee. Acta Orthop 83, 256\u2013260.","journal-title":"Acta Orthop"},{"key":"2790_CR54","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M., Bruce, I.N., D\u00f6rner, T., Tanaka, Y., Morand, E.F., Kalunian, K.C., Cardiel, M. H., Silk, M.E., Dickson, C.L., Meszaros, G., et al. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019.","journal-title":"Lancet"},{"key":"2790_CR55","doi-asserted-by":"publisher","first-page":"820046","DOI":"10.3389\/fimmu.2022.820046","volume":"13","author":"M Robert","year":"2022","unstructured":"Robert, M., Farese, H., and Miossec, P. (2022). Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front Immunol 13, 820046.","journal-title":"Front Immunol"},{"key":"2790_CR56","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto, N., Brunner, H.I., Synoverska, O., Ting, T.V., Mendoza, C.A., Spindler, A., Vyzhga, Y., Marzan, K., Grebenkina, L., Tirosh, I., et al. (2021). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398, 1984\u20131996.","journal-title":"Lancet"},{"key":"2790_CR57","doi-asserted-by":"publisher","first-page":"17231736","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn, W.J., Su, C., Sands, B.E., D\u2019Haens, G.R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B.G., Reinisch, W., Niezychowski, W., et al. (2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376, 17231736.","journal-title":"N Engl J Med"},{"key":"2790_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz, D.M., Bonelli, M., Gadina, M., and O\u2019Shea, J.J. (2016). Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12, 25\u201336.","journal-title":"Nat Rev Rheumatol"},{"key":"2790_CR59","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics 14, 1001.","journal-title":"Pharmaceutics"},{"key":"2790_CR60","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson, E.L., Lacour, J.-., Spelman, L., Galimberti, R., Eichenfield, L.F., Bissonnette, R., King, B.A., Thyssen, J.P., Silverberg, J.I., Bieber, T., et al. (2020). Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIII trials. Br J Dermatol 183, 242\u2013255.","journal-title":"Br J Dermatol"},{"key":"2790_CR61","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","volume":"191","author":"SJ Sohn","year":"2013","unstructured":"Sohn, S.J., Barrett, K., Van Abbema, A., Chang, C., Kohli, P.B., Kanda, H., Smith, J., Lai, Y., Zhou, A., Zhang, B., et al. (2013). A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 191, 2205\u20132216.","journal-title":"J Immunol"},{"key":"2790_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1074\/mcp.M700115-MCP200","volume":"7","author":"XC Song","year":"2008","unstructured":"Song, X.C., Fu, G., Yang, X., Jiang, Z., Wang, Y., and Zhou, G.W. (2008). Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics 7, 163\u2013169.","journal-title":"Mol Cell Proteomics"},{"key":"2790_CR63","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/pmic.200900585","volume":"10","author":"G Fu","year":"2010","unstructured":"Fu, G., Song, X.C., Yang, X., Peng, T., Wang, Y., and Zhou, G.W. (2010). Protein subcellular localization profiling of breast cancer cells by dissociable antibody microarray staining. PROTEOMICS 10, 1536\u20131544.","journal-title":"PROTEOMICS"},{"key":"2790_CR64","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/rheumatology\/keab024","volume":"60","author":"FR Spinelli","year":"2021","unstructured":"Spinelli, F.R., Colbert, R.A., and Gadina, M. (2021). JAK1: number one in the family; number one in inflammation? Rheumatology (Oxford) 60, ii3\u2013ii10.","journal-title":"Rheumatology (Oxford)"},{"key":"2790_CR65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","volume":"63","author":"EL Staals","year":"2016","unstructured":"Staals, E.L., Ferrari, S., Donati, D.M., and Palmerini, E. (2016). Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur J Cancer 63, 34\u201340.","journal-title":"Eur J Cancer"},{"key":"2790_CR66","doi-asserted-by":"publisher","first-page":"102491","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti, S., D\u00fcrr, H.R., Schaefer, I.M., Woertler, K., Haas, R., Trama, A., Caraceni, A., Bajpai, J., Baldi, G.G., Bernthal, N., et al. (2023). Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev 112, 102491.","journal-title":"Cancer Treat Rev"},{"key":"2790_CR67","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41467-017-02659-x","volume":"9","author":"W Stephenson","year":"2018","unstructured":"Stephenson, W., Donlin, L.T., Butler, A., Rozo, C., Bracken, B., Rashidfarrokhi, A., Goodman, S.M., Ivashkiv, L.B., Bykerk, V.P., Orange, D.E., et al. (2018). Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nat Commun 9, 791.","journal-title":"Nat Commun"},{"key":"2790_CR68","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., and Kaneko, Y. (2016). Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 75, 1057\u20131064.","journal-title":"Ann Rheum Dis"},{"key":"2790_CR69","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi, T., Tanaka, Y., Tanaka, S., Kawakami, A., Iwasaki, M., Katayama, K., Rokuda, M., Izutsu, H., Ushijima, S., Kaneko, Y., et al. (2019). Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 78, 1305\u20131319.","journal-title":"Ann Rheum Dis"},{"key":"2790_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-020-2125-2","volume":"22","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi, T., Tanaka, Y., Tanaka, S., Kawakami, A., Song, Y.W., Chen, Y.H., Rokuda, M., Izutsu, H., Ushijima, S., Kaneko, Y., et al. (2020). Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther 22, 47.","journal-title":"Arthritis Res Ther"},{"key":"2790_CR71","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka, Y., Takeuchi, T., Tanaka, S., Kawakami, A., Iwasaki, M., Song, Y.W., Chen, Y.H., Wei, J.C.C., Lee, S.H., Rokuda, M., et al. (2019). Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis 78, 1320\u20131332.","journal-title":"Ann Rheum Dis"},{"key":"2790_CR72","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap, W.D., Gelderblom, H., Palmerini, E., Desai, J., Bauer, S., Blay, J.Y., Alcindor, T., Ganjoo, K., Mart\u00edn-Broto, J., Ryan, C.W., et al. (2019). Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet 394, 478\u2013487.","journal-title":"Lancet"},{"key":"2790_CR73","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","volume":"28","author":"WD Tap","year":"2022","unstructured":"Tap, W.D., Singh, A.S., Anthony, S.P., Sterba, M., Zhang, C., Healey, J.H., Chmielowski, B., Cohn, A.L., Shapiro, G.I., Keedy, V.L., et al. (2022). Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. Clin Cancer Res 28, 298\u2013307.","journal-title":"Clin Cancer Res"},{"key":"2790_CR74","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap, W.D., Wainberg, Z.A., Anthony, S.P., Ibrahim, P.N., Zhang, C., Healey, J.H., Chmielowski, B., Staddon, A.P., Cohn, A.L., Shapiro, G.I., et al. (2015). Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 373, 428\u2013437.","journal-title":"N Engl J Med"},{"key":"2790_CR75","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1186\/s13018-023-04308-0","volume":"18","author":"TH Tseng","year":"2023","unstructured":"Tseng, T.H., Chen, C.L., Chang, C.H., Wang, J.H., and Young, T.H. (2023). IL-6 induces periostin production in human ACL remnants: a possible mechanism causing post-traumatic osteoarthritis. J Orthop Surg Res 18, 824.","journal-title":"J Orthop Surg Res"},{"key":"2790_CR76","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","volume":"28","author":"DGP van IJzendoorn","year":"2022","unstructured":"van IJzendoorn, D.G.P., Matusiak, M., Charville, G.W., Spierenburg, G., Varma, S., Colburg, D.R.C., van de Sande, M.A.J., van Langevelde, K., Mohler, D.G., Ganjoo, K. N., et al. (2022). Interactions in CSF1-driven tenosynovial giant cell tumors. Clin Cancer Res 28, 4934\u20134946.","journal-title":"Clin Cancer Res"},{"key":"2790_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"194","author":"AV Villarino","year":"2015","unstructured":"Villarino, A.V., Kanno, Y., Ferdinand, J.R., and O\u2019Shea, J.J. (2015). Mechanisms of Jak\/STAT signaling in immunity and disease. J Immunol 194, 21\u201327.","journal-title":"J Immunol"},{"key":"2790_CR78","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West, R.B., Rubin, B.P., Miller, M.A., Subramanian, S., Kaygusuz, G., Montgomery, K., Zhu, S., Marinelli, R.J., De Luca, A., Downs-Kelly, E., et al. (2006). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 103, 690\u2013695.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2790_CR79","doi-asserted-by":"publisher","first-page":"106566","DOI":"10.1016\/j.phrs.2022.106566","volume":"187","author":"C Xiang","year":"2023","unstructured":"Xiang, C., Li, H., and Tang, W. (2023). Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases. Pharmacol Res 187, 106566.","journal-title":"Pharmacol Res"},{"key":"2790_CR80","doi-asserted-by":"publisher","first-page":"665442","DOI":"10.3389\/fimmu.2021.665442","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Lv, J., Zhang, H., Xie, J., Dai, H., and Zhang, X. (2021). Gene expression profiles analyzed using integrating rna sequencing, and microarray reveals increased inflammatory response, proliferation, and osteoclastogenesis in pigmen-ted villonodular synovitis. Front Immunol 12, 665442.","journal-title":"Front Immunol"},{"key":"2790_CR81","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ygyno.2008.09.045","volume":"112","author":"X Zhu","year":"2009","unstructured":"Zhu, X., Lv, J., Yu, L., Zhu, X., Wu, J., Zou, S., and Jiang, S. (2009). Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol 112, 248\u2013256.","journal-title":"Gynecol Oncol"},{"key":"2790_CR82","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/ar142","volume":"3","author":"T Zimmermann","year":"2001","unstructured":"Zimmermann, T., Kunisch, E., Pfeiffer, R., Hirth, A., Stahl, H.D., Sack, U., Laube, A., Liesaus, E., Roth, A., Palombo-Kinne, E., et al. (2001). Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture \u2014 primary culture cells markedly differ from fourth-passage cells. Arthritis Res Ther 3, 72\u201376.","journal-title":"Arthritis Res Ther"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2790-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T19:38:09Z","timestamp":1740598689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2790-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2790"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2790-7","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}